Letters
Pathways to independence
Distancing design of phase III trials from drug company influence
BMJ 2020; 368 doi: https://doi.org/10.1136/bmj.m165 (Published 20 January 2020) Cite this as: BMJ 2020;368:m165
- Till Bruckner, founder
- TranspariMED, c/o Bristol Happy City, Canningford House, Bristol BS1 6BY, UK
- tillbruckner{at}gmail.com
Moynihan and colleagues propose ways to produce healthcare evidence independent of commercial interests.1
The design of pivotal phase III clinical trials is typically discussed in advance between regulators and drug companies, and the subsequent trials are often conducted by contract research organisations directly subcontracted by the drug company. Two small tweaks to this …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.